Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy

COGNITION THERAPEUTICS INC

Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.
MAGNIFY study enrolled 100 participants; final visits completed Feb 2025; full unblinded results expected Q2 2025.
Company concluding study early to preserve capital; plans to pursue indications in Alzheimer's and DLB.
Prior Phase 2 SHIMMER (DLB) showed 86% improvement on NPI; SHINE (Alzheimer's) showed 95% cognitive decline reduction in biomarker subgroup.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.